gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

PiCCO: a useful monitoring tool in 'triple H' therapy after severe subarachnoid hemorrhage

PiCCO: ein nützliches Monitoringswerkzeug bei der 'Triple H' Therapie nach der schweren Subarachnoidalblutung

Meeting Abstract

Suche in Medline nach

  • corresponding author A. F. Aliashkevich - Neurosurgical Department, University of Bonn Medical Center, Bonn
  • T. Kral - Neurosurgical Department, University of Bonn Medical Center, Bonn
  • C. Schaller - Neurosurgical Department, University of Bonn Medical Center, Bonn

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. DocP078

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2005/05dgnc0346.shtml

Veröffentlicht: 4. Mai 2005

© 2005 Aliashkevich et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

To estimate practical usefulness of pulse contour and transpulmonary thermodilutiuon monitoring (PiCCO, Pulsion Medical Systems, Munich) in the hypervolemic hypertension hemodilution ('triple H') therapy for cerebral vasospasm after severe subarachnoid hemorrhage (SAH).

Methods

A consecutive group of 20 patients after SAH who developed cerebral vasospasm was treated with aggressive 'triple H' therapy under PiCCO monitoring which demands availability of a central venous line and insertion of an arterial catheter with an embedded thermistor. It provides intermittent (transpulmonary thermodilution-derived) and continuous (pulse contour-derived) assessment of cardiac systolic function [cardiac output (CO), stroke volume (SV) and global ejection fraction (GEF)] and estimations of cardiac pre- and afterloads [e.g. global end-diastolic volume (GEDV), extravascular lung water (ELW), pulmonary vascular permeability index (PVPI) and systemic vascular resistance (SVR)]. These indices have been used to adjust the cathecholamine and volume management to prevent lung edema, hemodynamic failure during septic shock and/or multiorgan failure and to provide the optimal oxygenation in mechanically ventilated patients.

Results

One of 20 patients had SAH of Hunt and Hess grade II, n=12 were classified as grade III and n=7 as grade IV. In all, catecholamine therapy was established to treat or prevent hypoxic complications of vasospasm. No patient had mean arterial pressure <90 mm Hg or a cerebral perfusion pressure <65 mm Hg during therapy. There has been a significant consistency between the pulse-contour and thermodilution-derived parameters. The CO index ranged from 2 to 7 (median 4) l/min/m2, the GEF ranged from 11 to 39%, the SVR index ranged from 1543 to 4425 (median 2129) dyn×s×cm-5×m2, the ELW index was within 5 and 19.5 (median 8) ml/kg and the ITBV index ranged from 521 and 1247 (median 816) ml/m2. CO index was highly sensitive in the detection of hemodynamic changes but was less specific in determination of their origin (myocardial ischemia, septic shock, pulmonary edema etc.). One patient died of myocardial infarction, two sustained severe sepsis. Pulmonary edema could be early diagnosed in 5 cases by means of increased ELW index.

Conclusions

PiCCO is a minimally invasive tool for hemodynamic monitoring which may assist in the management of SAH-induced vasospasm and might be helpful for prediction of potential life-threatening complications of aggressive 'triple H' therapy.